NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Sample GSM1920942 Query DataSets for GSM1920942
Status Public on Aug 04, 2016
Title CiRA00009_iPSC derived endothelial cells_rep1
Sample type RNA
 
Source name ADPKD-specific iPSC derived endothelial cells
Organism Homo sapiens
Characteristics subject/sample source id: CiRA00009
subject status: autosomal dominant polycystic kidney disease (ADPKD) patient
gender: Female
cell type: iPSC derived endothelial cells
gender: Female
Growth protocol The differentiation of the iPSCs into vascular cells was carried out as described previously (Sone et al., 2007; Tatsumi et al., 2011). Briefly, undifferentiated human iPSCs were harvested and transferred to a collagen I-coated dish after adjusting the colonies to an appropriate size. On the second day of incubation, the culture medium was replaced with Primate ES medium without basic fibroblast growth factor (bFGF), supplemented with N2 supplement (Invitrogen)/B27 supplement (Invitrogen) and 6-bromoindirubin-3'-oxime (BIO, 5 μM, SIGMA). Thereafter, the cells were incubated for another 3 days, at which time the culture medium was replaced with StemPro-34 SFM (Invitrogen) supplemented with recombinant human vascular endothelial growth factor (VEGF, 50 ng/ml, PeproTech). After another 3–5 days of incubation, FLK1 (+) VE-cadherin (+) and FLK1 (+) VE-cadherin (-) cells were sorted individually using a FACSAria flow cytometer (BD). Sorted FLK1 (+) VE-cadherin (+) cells were confirmed to remain VE-cadherin positive during the subsequent cell culture and analyses. On the other hand, the sorted FLK1 (+) VE-cadherin (-) cells were differentiated into vascular smooth muscle cells after an additional 18-22 days of differentiation on collagen I-coated dishes supplemented with recombinant human platelet-derived growth factor-BB (PDGF-BB, 20 ng/ml, PeproTech).
Extracted molecule total RNA
Extraction protocol RNA was prepared using the miRNeasy Purification kit (Qiagen) following the manufacturer's recommendations. RNA was quantified using a NanoDrop-1000 spectrophotometer and quality was monitored with the Agilent 2100 Bioanalyzer (Agilent Technologies).
Label Cy3
Label protocol Manufature's protocol
 
Hybridization protocol Manufature's protocol
Scan protocol Slides were scanned on the G2565CA Microarray Scanner System (Agilent).
Description CiRA00009 EC
Gene expression of ADPKD-specific iPSC derived endothelial cells
Data processing Logbase 2-transformed signal data were normalized to the 75 percentile with baseline transformation to median of all samples by Agilent GeneSpring GX.
 
Submission date Oct 28, 2015
Last update date Aug 04, 2016
Contact name Akira Watanabe
E-mail(s) [email protected]
Organization name CyberomiX Inc
Street address Rm504, Miyako Bldg, 233, Isa-cho, kamigyo-ku
City Kyoto
State/province Kyoto
ZIP/Postal code 602-8407
Country Japan
 
Platform ID GPL17077
Series (2)
GSE74451 Identification of a novel risk factor for intracranial aneurysms in ADPKD using iPSC models [Agilent]
GSE74453 Identification of a novel risk factor for intracranial aneurysms in ADPKD using iPSC models

Data table header descriptions
ID_REF
VALUE Normalized signal intensity

Data table
ID_REF VALUE
GE_BrightCorner 8.037257
DarkCorner -6.4586926
A_23_P117082 4.4681597
A_33_P3246448 -6.4482427
A_33_P3318220 -6.564738
A_33_P3236322 -6.5658474
A_33_P3319925 -5.1260967
A_21_P0000509 5.267145
A_21_P0000744 1.1562681
A_24_P215804 -2.3408675
A_23_P110167 5.020239
A_33_P3211513 -1.8445125
A_23_P103349 -6.774379
A_32_P61480 -6.585022
A_33_P3788124 -6.5884137
A_33_P3414202 -1.2314467
A_33_P3316686 -1.4796128
A_33_P3300975 -3.275055
A_33_P3263061 4.1233234
A_33_P3261373 -6.604433

Total number of rows: 50739

Table truncated, full table size 1188 Kbytes.




Supplementary file Size Download File type/resource
GSM1920942_US94000320_253949424773_S01_GE1_1105_Oct12_1_3.txt.gz 3.0 Mb (ftp)(http) TXT
Processed data included within Sample table

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap